Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.05), Zacks reports.
Oric Pharmaceuticals Trading Up 6.4%
NASDAQ:ORIC opened at $8.00 on Wednesday. The company has a market capitalization of $829.20 million, a P/E ratio of -5.48 and a beta of 1.23. Oric Pharmaceuticals has a 12 month low of $7.23 and a 12 month high of $14.68. The firm has a fifty day simple moving average of $11.36 and a 200-day simple moving average of $10.98.
Insider Activity
In related news, CFO Dominic Piscitelli sold 77,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total value of $1,054,130.00. Following the transaction, the chief financial officer directly owned 69,828 shares of the company’s stock, valued at $955,945.32. This represents a 52.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 105,000 shares of company stock valued at $1,432,952. 5.70% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
View Our Latest Report on ORIC
Oric Pharmaceuticals Company Profile
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Read More
- Five stocks we like better than Oric Pharmaceuticals
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
